Answer
Regorafenib (Stivarga) monotherapy is indicated for adults with metastatic colorectal cancer previously treated with, or not considered candidates for, available therapies, including fluoropyrimidine-based chemotherapy, an anti-VEGF therapy and an anti-EGFR therapy.
Sources for this answer
- Stivarga 40 mg film coated tabletsBayer plc · emc · SmPC §4.1 Therapeutic Indications · Version 7Document updated
Sources checked